Vivanza Biosciences Approves Quarterly Results for Q ended June 30, 2026
Vivanza Biosciences Ltd. has announced its Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The company's Board of Directors reviewed and approved these results at a meeting held on August 7, 2026, along with reviewing declarations from directors and confirming independent director criteria.The limited review reports, conducted by Statutory Auditors Shivam Soni & Co., confirmed that the statements complied with applicable accounting standards for both the standalone and consolidated entities. The company operates across three segments: Pharmaceuticals, Agro, and Film-related activities.
Standalone Financial Results (Q ended June 30, 2026)
The Unaudited Standalone Financial Results showed various performance indicators for the quarter. A brief summary of key figures in Rs. in Lacs is provided below:| Particulars | Quarter Ended 30/06/2026 (Unaudited) | Quarter Ended 31/03/2026 (Audited) | Quarter Ended 30/06/2025 (Unaudited) | Year Ended 31/03/2026 (Audited) |
|---|---|---|---|---|
| Revenue from operations | 914.09 | 574.60 | 782.05 | 11,223.10 |
| Other Income | 37.28 | 0.77 | 1.74 | 10.94 |
| Total Income | 951.37 | 575.37 | 783.81 | 11,234.04 |
| Purchase of stock-in-trade | 932.73 | 533.56 | 770.95 | 11,207.08 |
| Employee benefits expense | 9.56 | 3.84 | 9.22 | 33.08 |
| Finance Cost | 10.62 | 6.58 | 7.66 | 27.92 |
| Total Expenses | 933.29 | 587.69 | 781.95 | 11,182.25 |
| Profit before tax | 18.08 | -12.32 | 1.86 | 51.79 |
| Profit for the period from continuing operations | 14.51 | -26.61 | 1.86 | 37.50 |
Consolidated Financial Results (Q ended June 30, 2026)
The Unaudited Consolidated Financial Results presented figures across the group entity for the quarter ending June 30, 2026. Key highlights from the consolidated results are summarized below:| Particulars | Quarter Ended 30/06/2026 (Unaudited) | Quarter Ended 31/03/2026 (Audited) | Quarter Ended 30/06/2025 (Unaudited) | Year Ended 31/03/2026 (Audited) |
|---|---|---|---|---|
| Revenue from operations | 928.97 | 636.29 | 893.92 | 11,591.06 |
| Other Income | 37.28 | 0.86 | 1.74 | 11.15 |
| Total Income | 966.25 | 637.15 | 895.66 | 11,602.21 |
| Purchase of stock-in-trade | 947.31 | 595.93 | 961.25 | 11,571.38 |
| Employee benefits expense | 9.56 | 6.74 | 13.64 | 49.24 |
| Finance Cost | 10.62 | 6.58 | 7.66 | 27.92 |
| Total Expenses | 948.01 | 667.30 | 886.96 | 11,547.84 |
| Profit before tax | 18.24 | -30.15 | 8.70 | 54.37 |
| Profit for the period from continuing operations | 14.67 | -45.08 | 8.70 | 39.44 |
The company confirmed that it adopted Ind AS, effective April 1, 2017, and all financial results have been prepared in accordance with Indian Accounting Standards (Ind AS).
Stock Price Movement
As of 10:14, Vivanza Biosciences Ltd shares are ticking down at ₹1.88, reflecting a 0.53% decline from the previous close. The company's shares traded within a tight intraday range, moving between a low of ₹1.88 and a high of ₹1.89.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.